Global Medical Affairs
RAD001 (Everolimus)
Afinitor
Oncology Clinical Protocol CRAD001C2X01B 1&7
An open-label, multi-center everolimus roll-over protocol 
for patients who have completed a previous Novartis-
sponsored everolimus study and are judged by the 
investigator to benefit from continued everolimus 
treatment
Authors
Document type Amended Protocol VersionEUDRACT number 2012-004707-12Version number 01 (Amendment) (Clean)Development phase IVDocument status FinalRelease date 18-Mar-2016
Property of Novartis
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of Novartis
Template version 19-Nov-2015PPD
Novartis Confidentia l Page 2
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
Table of contents
Table of contents ................................................................................................................. 2
List of figures ...................................................................................................................... 5
List of tables ........................................................................................................................ 5
List of abbreviations ............................................................................................................ 6
Glossary  of terms ................................................................................................................. 7
Amendment 01 (18 -Mar-2016) ........................................................................................... 9
Protocol summary :............................................................................................................. 11
1Background ........................................................................................................................ 13
1.1 Overview of disease pathogenesis, epidemiology and current treatment .............. 13
1.2 Introduction to investigational treatment(s) and other study  treatment(s) ............. 13
1.2.1 Overview of everolimus........................................................................ 13
2Rationale ............................................................................................................................ 16
2.1 Study  rationale and purpose ................................................................................... 16
2.2 Rationale for the stud y design ............................................................................... 16
2.3 Rationale for dose and regimen selection .............................................................. 16
2.4 Rationale for choice of combination drugs............................................................ 17
2.5 Rationale for choice of comparators drugs ............................................................ 17
2.6 Risks & Benefits .................................................................................................... 17
3Objectives and endpoints ................................................................................................... 18
4Study  design ...................................................................................................................... 20
4.1 Description of stud y design ................................................................................... 20
4.2 Timing of interim anal yses and design adaptations ............................................... 21
4.3 Definition of end of study ...................................................................................... 21
4.4 Early study termination .......................................................................................... 21
5Population .......................................................................................................................... 21
5.1 Patient population .................................................................................................. 21
5.2 Inclusion criteria .................................................................................................... 21
5.3 Exclusion criteria ................................................................................................... 22
6Treatment ........................................................................................................................... 23
6.1 Study  treatment ...................................................................................................... 23
6.1.1 Dosing regimen ..................................................................................... 23
6.1.2 Ancillary  treatments .............................................................................. 24
6.1.3 Rescue medication ................................................................................ 24
6.1.4 Guidelines for continuation of treatment .............................................. 24
6.1.5 Treatment duration ................................................................................ 24

Novartis Confidentia l Page 3
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
6.2 Dose escalation guidelines ..................................................................................... 24
6.3 Dose modifications ................................................................................................ 24
6.3.1 Dose modification and dose delay ........................................................ 24
6.3.2 Follow- up for toxicities ......................................................................... 25
6.3.3 Anticipated risks and safety  concerns of the study drug ....................... 26
6.4 Concomitant medications ...................................................................................... 26
6.4.1 Permitted concomitant therap y ............................................................. 26
6.4.2 Permitted concomitant therap y requiring caution and/or action ........... 26
6.4.3 Prohibited concomitant therap y ............................................................ 28
6.4.4 Use of Bisphosphonates (or other concomitant agents) ........................ 28
6.5 Patient numbering, treatment as signment or randomization ................................. 28
6.5.1 Patient numbering ................................................................................. 28
6.5.2 Treatme nt assignment or randomization ............................................... 29
6.5.3 Treatment blinding ................................................................................ 29
6.6 Study  drug preparation and dispensation ............................................................... 29
6.6.1 Study  treatment packaging and labeling ............................................... 29
6.6.2 Drug supply  and storage ........................................................................ 30
6.6.3 Study  drug compliance and accountabilit y ........................................... 30
6.6.4 Disposal and destruction ....................................................................... 31
7 Visit schedule and assessments ......................................................................................... 31
7.1 Study  flow and visit schedule ................................................................................ 31
7.1.1 Molecular pre -screening ........................................................................ 33
7.1.2 Screening ............................................................................................... 33
7.1.3 Run- in period ........................................................................................ 33
7.1.4 Treatment period ................................................................................... 33
7.1.5 Discontinuation of study  treatment ....................................................... 33
7.1.6 Follow up for safet y evaluations ........................................................... 35
7.1.7 Lost to f ollow-up................................................................................... 35
7.2 Assessment ty pes................................................................................................... 35
7.2.1 Efficacy  assessments ............................................................................. 35
7.2.2 Safety  and tolerability  assessments ....................................................... 35
7.2.3 Pharmacokinetics .................................................................................. 35
7.2.4 Biomarkers ............................................................................................ 35
7.2.5 Resource utilization ............................................................................... 36
7.2.6 Patient reported outcomes ..................................................................... 36
8Safety  monitoring and reporting ........................................................................................ 36

Novartis Confidentia l Page 4
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
8.1 Adverse events ....................................................................................................... 36
8.1.1 Definitions and reporting ...................................................................... 36
8.1.2 Laboratory  test abnormalities ................................................................ 37
8.1.3 Adverse events of special interest ......................................................... 38
8.2 Serious adverse events ........................................................................................... 38
8.2.1 Definitions............................................................................................. 38
8.2.2 Reporting............................................................................................... 39
8.3 Emergency  unblinding of treatment assignment ................................................... 40
8.4 Pregnancies ............................................................................................................ 40
8.5 Warnings and precautions ...................................................................................... 40
8.6 Data Monitoring Committee .................................................................................. 40
8.7 Steering Committee ............................................................................................... 41
9Data collection and management ....................................................................................... 41
9.1 Data confidentiality ............................................................................................... 41
9.2 Site monitoring ...................................................................................................... 41
9.3 Data collection....................................................................................................... 42
9.4 Database management and quality  control ............................................................ 42
10Statistical methods and data anal ysis................................................................................ 42
10.1 Analy sis sets .......................................................................................................... 42
10.1.1 Full Anal ysis Set ................................................................................... 42
10.1.2 Safety  set............................................................................................... 42
10.1.3 Dose -determining anal ysis set............................................................... 43
10.2 Patient demographics/other baseline characteristics ............................................. 43
10.3 Treatments (stud y treatment, compliance) ............................................................ 43
10.4 Primary  objective ................................................................................................... 43
10.4.1 Variable ................................................................................................. 43
10.4.2 Statistical hy pothesis, model, and method of analy sis.......................... 43
10.4.3 Handling of missing values/censoring/discontinuations ....................... 43
10.4.4 Supportive and Sensitivity anal yses...................................................... 43
10.5 Secondary  objectives ............................................................................................. 43
10.5.1 Key secondary  objective(s) ................................................................... 43
10.5.2 Other secondary  efficacy objectives ..................................................... 43
10.5.3 Safety  objectives ................................................................................... 43
10.6 Exploratory  objectives ........................................................................................... 44
10.7 Interim anal ysis...................................................................................................... 44
10.8 Sample size calculation.......................................................................................... 44

Novartis Confidentia l Page 5
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
10.9 Power for anal ysis of key secondary  variables...................................................... 44
11Ethical considerations and administrative procedures ...................................................... 45
11.1 Regulatory and ethical compliance ........................................................................ 45
11.2 Responsibilities o f the investigator and IRB/ IEC/REB ......................................... 45
11.3 Informed consent procedures................................................................................. 45
11.4 Discontinuation of the study .................................................................................. 46
11.5 Publication of study  protocol and results ............................................................... 46
11.6 Study  documentation, record keeping and retention of documents....................... 46
11.7 Confidentiality  of study  documents and patient records ....................................... 47
11.8 Audits and inspections........................................................................................... 47
11.9 Financial disclosures .............................................................................................. 47
12Protocol adherence ............................................................................................................ 47
12.1 Amendments to the protocol .................................................................................. 47
13References (available upon request) .................................................................................. 48
List of figures
Figure 4-1 Study  design .......................................................................................... 20
List of tables
Table 3 -1 Objectives and related endpoints .......................................................... 19
Table 6 -1 Dose and treatment schedule................................................................. 23
Table 6 -2 Combination therapy  dose and treatment schedule ............................... 23
Table 6 -3 Clinically  relevant drug interactions: inducers, and inhibitors of 
isoenzy me CYP3A ................................................................................ 27
Table 6 -4 Clinically  relevant drug interactions: substrates, inducers, 
inhibitors of PgP and PgP/CYP3A dual inhibitors ............................... 28
Table 6 -5 Preparation and dispensing ................................................................... 29
Table 6 -6 Packaging and labeling ......................................................................... 29
Table 6 -7 Supply  and storage of study  treatments ................................................ 30
Table 7 -1 Visit evaluation schedule ...................................................................... 32

Novartis Confidentia l Page 6
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
List of abbreviations
AE Adverse Event
BSC Best Supportive Care
CRF Case Report/Record Form; the term CRF can be applied to either EDC or Paper
CRO Contract Research Organization
CSR Clinical study report
EC European Commission
IB Investigatorâ€™s Brochure
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IIT Investigator -initiated Trial
IRB Institutional Review Board
mTOR mammalian Target of Rapamy cin
OGD&GMA Oncology Global Development and Global Medical Affairs 
o.d. omnia die/once a day
PI Principal Investigator
p.o. per os/by mouth/orally
REB Research Ethics Board
SAE Serious Adverse Event
SOP Standard Operating Procedure

Novartis Confidentia l Page 7
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
Glossary  of terms
Assessment A procedure used to generate data required by the study
Control drug A study treatment used as a comparator to reduce assessment bias, 
preserve blinding of investigational drug, assess internal study valid ity, 
and/or evaluate comparative effects of the investigational drug
Cycles Number and timing or recommended repetitions of therapy are usually 
expressed as number of days (e.g.: q28 days)
Dose level The dose of drug given to the patient (total daily or weekly  etc.) 
Enrollment Point/time of patient entry into the study; the point at which informed 
consent must be obtained (i.e. prior to starting any of the procedures 
described in the protocol)
Inves tigational treatment Drug whose properties are being tested in the study as well as their 
associated placebo and active treatment controls (when applicable). 
This also includes approved drugs used outside of their 
indication/approved dosage, or that are te sted in a fixed combination. 
Investigational treatment generally does not include other study 
treatments administered as concomitant background therapy required 
or allowed by the protocol when used in within approved 
indication/dosage
Medication number A unique identifier on the label of each study treatment package which 
is linked to one of the treatment groups of a study
Other study treatment Any drug administered to the patient as part of the required study 
procedures that was not included in the inves tigational treatment
Patient Number (Patient No) A unique identifying number assigned to each patient/subject/healthy 
volunteer who enrolls in the study
Roll-over study A roll -over study allows patients from multiple parent studies spanning 
multiple indications to continue to be treated within one study after the 
completion of the parent study(ies)
Stage in cancer The extent of a cancer in the body. Staging is usually based on the 
size of the tumor, whether lymph nodes contain cancer, and whether 
thecancer has spread from the original site to other parts of the body
Stop study participation Point/time at which the patient came in for a final evaluation visit or 
when study treatment was discontinued whichever is later
Study treatment Includes any dr ug or combination of drugs in any study arm 
administered to the patient (subject) as part of the required study 
procedures, including placebo and active drug run -ins.
In specific examples, it is important to judge investigational treatment 
component relati onship relative to a study treatment combination; 
study treatment in this case refers to the investigational and non -
investigational treatments in combination.
Study treatment 
discontinuationPoint/time when patient permanently stops taking study treatment for 
any reason
Supportive treatment Refers to any treatment required by the exposure to a study treatment, 
e.g. premedication of vitamin supplementation and corticosteroid for 
pemetrexed disodium.
Treatment group A treatment group defines the dose and regimen or the combination, 
and may consist of 1 or more cohorts. Cohorts are not expanded, new 
cohorts are enrolled.

Novartis Confidentia l Page 8
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
Variable Identifier used in the data analysis; derived directly or indirectly from 
data collected using specified assessments at specified timepoints
Withdrawal of co nsent Withdrawal of co nsent occurs only wh en a patient d oes not want to 
partic ipate in the study any longer, a nd does n ot want any further visits 
or assessments, and does not want any further study related cont act

Novartis Confidentia l Page 9
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
Amendment 01 (18-Mar-2016)
Amendment rationale 
The main purpose of the amendment is to change the primary  endpoint to safet y to better 
characterize the long-term safet y of the compound.  In addition, the protocol has been 
amended to include the collection of all AEs (including non-serious AEs) and an investigator 
attestation of continued clinical benefit.
This roll-over study  has been opened since 13-May-2013 with 32 patients enrolled and 21
patients ongoing.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The following changes have been implemented: 
Section 1.1: Removed the purpose of the study as this was redundant to Section 2.1.
Section 1.2.1: Overview language updated based on IB update.
Section 1.2.1.2: Clinical experience language updated based on IB update .
Section 2.1: Updated purpose to reflect new primary  endpoint .
Section 2.2: Updated ratio nale to reflect new primary  endpoint.
Table 3-1: Updated with revised study  objectives.  The primary  objective is to evaluate long 
term safety  data. The secondary  objective is to evaluate clinical benefit as assessed by the 
investigator.
Section 4.1: Updat ed description of study  to reflect new primary  endpoint and to clarify  that 
all adverse events and serious adverse events will be collected continuously  throughout the 
study .  Visit frequency  updated to quarterl y.  Updated to specify  that at every  visit, the 
investigator is required to confirm that the patient continues to have clinical benefit and may 
continue receiving stud y treatment . 
Section 4.2: Updated to reflect that interim analy ses are not applicable.
Section 4.3: Updated definition of the end of study.
Section 5.3: Updated contraception language based on new guidelines on pregnancy 
prevention .
Section 6.1: Removed reference to drug shipments to sites.
Section 6.1.5: Updated to specify  that at every  visit, the investigator is required to confirm 
that the patient continues to have clinical benefit and may  continue receiving study  treatment.
Section 6.3.1: Added reference to IB for dose modifications.
Section 6.3.2: Added that patients will be followed for adverse events in addition to serious 
adverse events.

Novartis Confidentia l Page 10
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
Section 6.3.2.1: New section a dded for drug-induced liver toxicity  language .
Section 6.4: Added reference to IB for use concomitant medications.
Table 6 -3: Updated inducers, and inhibitors of isoenzy me CYP3A based on IB update.
Table 6-4: Updated substrates, inducers, inhibitors of PgP and PgP/CYP3A dual inhibitors 
based on IB update .
Section 6.4.2: Updated vaccination languagebased on IB update .
Table 6 -5: Updated to reflect change to quarterly visits.
Table 7-1: Updated to include investigator attestation of clinical benefit at every  quarterl y 
visit, collection of all adverse events, relevant medical history , monthly  at home pregnancy 
testing for female patients of child bearing potential and the study  evaluation completion 
eCRF page at the end of the 30 day  safet y follow up.
Section 7.1.2.3: Updated to reflect collection of demographics and relevant medical history .
Section 7.1.4: Updated to specify  amount of drug suppl y to be provided, visits are quarterl y, 
and that the investigator is required to confirm that the patient continues to have clinical 
benefit at every  visit and may  continue receiving study  treatment.
Section 7.1.5: Section name updated.   
Section 7.1.5.1: Section name updated in addition to adding ne w language.
Section 7.1.6: Section name updated.  Added stipulation that adverse events be collected.
Section 7.1.6.1: Added new section for study  evaluation completion.
Section 7.1.7: Added L ost to follow up language .
Section 7.2.1: Updated to specify  that the investigator is required to confirm that the patient 
continues to have clinical benefit at every  visit and may  continue receiving study  treatment.
Section 7.2.2: Updated pregnancy  testing language.
Section 8: Updated with new AE/SAE reporting process .
Section 10: Updated statistical anal ysis section based on revised stud y objectives.
Section 11.4: Added reference to Section 4.4.
Section 13: Removed references no longer used.
References to the parent protocol have been removed in favor of a newer sourc e that can be 
used (for example, the IB), as applicable.  The protocol summary  has also been updated to 
reflect the above changes, as applicable.
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Comm ittee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.

Novartis Confidentia l Page 11
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
Protocol summary : 
Title An open label, multi -center everolimus roll- over protocol for patients who have 
completed a previ ous Novartis -sponsored everolimus study and are judged by the 
investigator to benefit from continued everolimus treatment.
Sponsor and Clinical Phase Novartis, IV.
Investigation type Drug .
Study type Interventional.
Purpose and rationale The purpose of this study is to better characterize the long -term safety of
everolimus in patients who are on everolimus treatment in a Novartis -sponsored, 
Oncology Global Development & Global Medical Affairs ( OGD&GMA) study and 
are benefiting from the tr eatment as judged by the investigator.
Primary Objective To evaluate long term safety data .
Secondary Objectives To evaluate clinical benefit as assessed by the investigator 
Study design This is a multi -center, open label study to better characterize the long -term safety
of everolimus inpatients being treated in current Novartis- sponsored OGD&GMA
studies and who are benefiting from treatment with everolimus as judged by the 
investigator . There will be no screening period for this study. Eligible patie nts are to 
be consented and can start their treatment with everolimus as soon as they enter 
the study. All patients must report to the study site for their first visit at which time, 
a quarterly supply of everolimus can be dispensed to the patient /or as per local 
practice .
Patients must return to the study center on a quarterly basis 12 weeks +/ -1 week ) 
for resupply of study medication at which time drug dispensing information and 
adverse events will be collected. The patient may return to the clinic at any given 
time as per standard of care, however, only four study visits per year will be 
recorded. All adverse events and serious adverse events will be collected 
continuously throughout the study .
Patients will continue to be treated until they are no lo nger benefiting from 
everolimus as judged by the investigator (disease progression), develop 
unacceptable toxicities, withdraw consent, are non- compliant to the protocol, or the 
patient dies, whichever comes first.
A patient will reach the end of study when everolimus treatment is permanently 
discontinued and the end of treatment visit has been performed. All patients must 
be followed for adverse events and serious adverse events for 30 days after the 
last dose of study treatment. Following this there are no further follow -up study 
visits.
The study is expected to remain open for 10 years or until such time that enrolled 
patients no longer need treatment with everolimus or are able to obtain commercial 
supply according to local regulations for their medical conditions. 
Population Male and female patients, who are currently enrolled in a Novartis -sponsored, 
OGD&GMA everolimus study, are benefiting from treatment with everolimus and 
have fulfilled all their requirements in the parent study. All objectives of the parent 
study must have been reached, and the study must be in the process of being 
completed & reported. Approximately 50 patients may enroll into this study.
Inclusion criteria Patient is currently enrolled in a Novartis -sponsored , Oncology Clinical 
Development & Medical Affairs study receiving everolimus and has fulfilled all their 
requirements in the parent study.
Patient is currently benefiting from the treatment with everolimus, as determined by 
the parent study criteria.
Patie nt has demonstrated compliance, as assessed by the investigator, with the 
parent study protocol requirements.

Novartis Confidentia l Page 12
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
Exclusion criteria Patient has been permanently discontinued from everolimus study treatment in the 
parent study due any reason.
Patient has part icipated in a Novartis sponsored combination trial where 
everolimus was dispensed in combination with unapproved or experimental 
treatments and is still receiving the unapproved or experimental treatment. 
Investigational and 
reference therapyEverolimus, 2.5 -10 mg/day.
Efficacy assessments At every quarterly visit, the investigator is required to confirm that the patient 
continues to have clinical benefit and may continue receiving study treatment.
Safety assessments All adverse events and serious adverse events will be collected continuously 
throughout the study.
Other assessments Not applicable.
Data analysis Proportion of patients with clinical benefit as assessed by the investigator will be 
summarized at scheduled visits. The assessment of saf ety will be based mainly on 
the frequency of AEs and SAEs .
Key words Everolimus roll -over study to better characterize the long term -term safety of 
everolimus inpatients receiving everolimus in a Novartis -sponsored OGD&GMA
study which has reached its objectives and who are benefiting from treatment with 
everolimus.

Novartis Confidentia l Page 13
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
1 Background
1.1 Overview of disease pathogenesis, epidemiology  and current 
treatment
The roll-over study  is designed to accept patients with varied disease origins. Please refer to 
the parent protocol for the disease background information and rationale for use of everolimus 
in their individual indications.  See Section 1.2.1.2 .
1.2 Introduction to investigational treatment(s) and other study  
treatment(s)
1.2.1 Overview  of everolimus
Everolimus is a signal transduction inhibitor (STI) targeting mTOR, or more specificall y, 
mTORC1 (mammalian 'target of rapam ycin' complex 1). mTOR is a key serine -threonine 
kinase playing a central role in the regulation of cell growth, proliferation and survival. The 
regulation of mTORC1 signaling is complex, being modulated by mitogens, growth factors, 
energy  and nut rient availability . mTORC1 is an essential regulator of global protein synthesis 
downstream on the PI3K/AKT/mTOR pathway , which is dysregulated in the majority  of 
human cancers (Boulay  and Lane 2007 ). Consistent with the known activity  of mTORC1, its 
inhibition by everolimus has been shown to reduce cell proliferation, glycolysis and 
angiogenesis in solid tumors in vivo, both through direct antitumor cell activity  and inhibition 
of the tumor stromal comp artment.
mTOR is a key regulatory  protein affecting various cell functions (Boulay  and Lane 2007 ). 
The main known functions of mTOR include:
ï‚·Function as a sensor of mitogens, growth factors, energy  and nutrient levels, facilitating 
cell-cycle progression through the G1 to -
S-phase in appropriate growth conditions.
ï‚·Regulation of protein sy nthesis important for tumor cell proliferation and angiogenesis 
through inactivating eukary otic initiation factor 4E binding proteins and activating the 40S 
ribosomal S6 kinases (e.g. p70S6K1). For example, activation of the mTOR pathway  
leads to:
ï‚·Increased production of pro -angiogenic factors (e.g. VEGF) in tumors.
ï‚·Tumor, endothelial and smooth muscle cell growth and pr oliferation.
1.2.1.1 Non-clinical experience
For latest information on the pre-clinical pharmacology  and toxicology  of everolimus please 
refer to the current Investigator Brochure (IB).
1.2.1.2 Clinical experience
In oncology , everolimus has been in clinical development s ince 2002 for patients with various 
hematologic and non-hematologic malignancies; as a single agent or in combination with 
antitumor agents. Malignancies that are currently  being evaluated in Novartis sponsored 

Novartis Confidentia l Page 14
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
studies include the following: metastatic renal cell carcinoma (mRCC), breast cancer, 
pancreatic neuroendocrine tumors (pNET/ NET), diffuse large B cell lymphoma (DLBCL), 
and hepatocellular cancer (HCC). In addition, treatment of patients with tuberous sclerosis 
complex (TSC) associated subepend ymal giant cell astrocy toma (SEGA) ,renal 
angiom yolipoma , and epilepsy are also being evaluated.
Phase I dose escalating studies, exploratory  Phase I/II/III studies with everolimus as single 
agent or in combination with other anti-cancer agents, Phase II/III studies of everolimus in 
different indications, Phase III double -blind studies and Phase IV studies are contributing to 
the extensive clinical database.
Approximately  27,399 patients, (excluding those patients who received marketed 
AfinitorÂ®/VotubiaÂ®, those on planned and roll over studies as well as excluding investigator -
sponsored studies) have been enrolled in studies with everolimus as of 31 -Mar-2015.
Oncology
Everolimus was approved by FDA on 30- Mar-2009 under the trade name AfinitorÂ®for the 
treatment o f patients with advanced RCC after failure of treatment with sunitinib or sorafenib. 
The European Commission (EC) approved AfinitorÂ®on 03- Aug-2009 for the treatment of 
patients with advanced RCC, whose disease has progressed on or after treatment with vas cular 
endothelial growth factor (VEGF) -targeted therapy . As of 31-Mar-2015, AfinitorÂ®has been 
approved in 121 countries worldwide for the treatment of patients with advanced RCC.
On 05 -May-2011, FDA approved AfinitorÂ®for the â€œtreatment of progressive pNE T in patients 
with unresectable, locally  advanced or metastatic disease. Afinitor is not indicated for the 
treatment of patients with functional carcinoid tumorsâ€. The EC approved AfinitorÂ®on 24-
Aug-2011 for the treatment of unresectable or metastatic, well-or moderately -differentiated 
neuroendocrine tumors of pancreatic origin in adults with progressive disease. As of 31-Mar-
2015, AfinitorÂ®has been approved in >115 countries worldwide for the treatment of patients 
with pNET/neuroendocrine tumors.
On 20-Jul-2012, FDA approved AfinitorÂ®for the treatment of postmenopausal women with 
advanced hormone receptor -positive, HER2- negative breast cancer in combination with 
exemestane, after failure of treatment with letrozole or anastrozole. The EC approved 
AfinitorÂ®on 23- Jul-2012 for the treatment of hormone receptor -positive, HER2/neu negative 
advanced breast cancer, in combination with exemestane, in postmenopausal women without 
symptomatic visceral disease after recurrence or progression following a non- steroidal 
aromatase inhibitor. As of 31-Mar-2015, AfinitorÂ®has been approved in >115 countries for 
the treatment of patients with advanced hormone receptor -positive, HER2 -negative breast 
cancer.
Tuberous sclerosis complex
AfinitorÂ®received accelerated approval from FDA on 29- Oct-2010 for the â€œtreatment of 
patients with SEGA associated with tuberous sclerosis complex (TSC) who require 
therapeutic intervention but are not candidates for curative surgical resection. The EC granted 
conditional approval on 02-Sep-2011 for everolimus under the trade name VotubiaÂ®for the 
â€œtreatment of patients aged 3 years and older with SEGA associated with TSC who require 

Novartis Confidentia l Page 15
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
therapeutic intervention but are not amenable to surgery .  AfinitorÂ®received accelerated 
approval from FDA on 26-Apr-2012 for the â€œtreatment of adult patients with renal 
angiom yolipoma and TSC, not requiring immediate surgery
For further details please refer to the current everolimus IB.
Pharmacokinetics
Everolimus is rapidly  absorbed after oral administration, with a median time to peak blood 
levels (tmax) of 1-2 hours postdose. The extent of absorption is estimated at above 11%. The 
area under the blood concentration -time curve (AUC) is dose -proportional over the dose range 
of 5 to 70mg tested while maximum blood concentration Cmaxappears to plateau at dose 
levels higher than 20 mg. The terminal half -life in cancer patients averaged 30 hours, which is 
similar to that in healthy subjects. A high-fat meal altered the absorption of everolimus with 
1.3 hour delay  in tmax, a 60% reduction in Cmaxand a 16% reduction in AUC. In whole blood, 
approximately  80% of everolimus is contained in red blood cells. Of the fraction of drug 
contained in plasma, 74% is protein -bound. The apparent distri bution volume (Vz/F) after a 
single dose was 4.7 L/kg. Everolimus is eliminated by metabolism, mainly by hydroxylation, 
then excreted into the feces >80%.
Everolimus is mainly  metabolized by  CYP3A4 in the liver and to some extent in the intestinal 
wall. Everolimus is also a substrate of P-glycoprotein (PgP). Therefore, absorption and 
subsequent elimination of systematicall y absorbed everolimus may be influenced by 
medicinal products that interact with CYP3A4 and/or P-glycoprotein. In vitro studies showed 
that everolimus is a competitive inhibitor of CYP3A4 and of CYP2D6 substrates, potentiall y 
increasing the concentrations of medicinal products eliminated by these enzymes. In two 
phase III clinical trials in patients following kidney  transplantation, strong inhibitors of 
CYP3A4 (azoles, antifungals, cyclosporine, erythromy cin) have been shown to reduce the 
clearance of everolimus therap y thereby  increasing everolimus blood levels. Similarly , 
Rifampin, a strong inducer of CYP3A4, increases the clearance of everolimus thereb y 
reducing everolimus blood levels. Another drug-drug interaction study  of everolimus 
administered with a sensitive CYP3A4 substrate midazolam showed that while everolimus did 
not influence the hepatic metabolism of midazolam, it led to minor increases in bioavailability  
of midazolam likely  due to influences of pre -systemic metabolism. Caution should be 
exercised when co-administering everolimus with CYP3A4 inhibitors, inducers, or substrates 
with a narrow therapeutic index.
Pharmacody namic st udies
Pharmacokinetic/pharmacody namic modeling based on inhibition in a peripheral biomarker 
(S6 kinase inhibition in peripheral blood mononuclear cells) suggests that 5 to 10 mg daily 
should be an adequate dose to produce a high-degree of sustained target inhibition. 
Furthermore, molecular pharmacod ynamic (MPD) studies using IHC in biopsied tumor tissue 
assessed the degree of inhibition and its duration (for p-S6, p-4E- BP1 and p-Akt expression) 
with the daily  and weekly  dosing. The pathologist was blinded for the biopsy  sequence. There 
was almost complete inhibition of p-S6 at all doses and schedules studied (p=0.001). 
Preliminary  results suggest a dose -related decrease in p-4E- BP1 and increase in p-Akt 
expression with maximal effect at 10 mg dail y and â‰¥50 mg weekly . 

Novartis Confidentia l Page 16
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
For further details please refer to the current everolimus IB.
2 Rationale
2.1 Stud y rationale and purpose
The purpose of this study  is to better characterize the long-term safety of everolimus in 
patients who are currently  receiving everolimus treatment in a Novartis -sponsored, 
OGD&GMA study  that has reached its study  objectives andare not progressing on the current 
study  treatment as judged by the investigator .Parent studies eligible to participate in the roll-
over study  will be decided by  Novartis. Investigator initiated trials (IITs) will not be included. 
The primary  objective of the parent study  must have been reached and the parent study  must 
be in the proc ess of being completed and reported.
Patients will continue to receive everolimus until one of the following occurs: no treatment 
benefit (disease progression) as judged by the investigator , unacceptable toxicity  develops, 
consent withdrawal, protocol non-compliance, the investigator feels it is no longer in the 
patientâ€™s best interest to continue therap y, or the patientâ€™s death.
The roll-over protocol is designed to provide continued treatment with everolimus 
monotherap y to patients. If patients are receiv ing treatment of everolimus in combination with 
other approved therapies, they can participate in the roll-over study , but it is not intended for 
combination with unapproved or experimental treatments.  Therefore, patients may be 
allowed to continue combination therapy  with Sandostatin LARÂ®Depot if they are currentl y 
receiving this combination therapy  on the parent protocol and at the discretion of the 
investigator. Sandostatin LARÂ®Depot is a formulation of octreotide which can be 
administered on a once m onthly  schedule and is available commerciall y worldwide. 
Sandostatin LARÂ®Depot has been used to treat the symptoms associated with metastatic 
carcinoid tumors (flushing and diarrhea), and vasoactive intestinal peptide (VIP) secreting 
adenomas (watery  diarrhea).  For additional details please refer to the national prescribing 
information.
2.2 Rationale for the study  design
This is a multi -center, open -label, phase IV study  to better characterize the long -term safet y of
everolimus in patients being treated in acurrent Novartis -sponsored, OGD&GMA study  and 
who are benefiting from treatment with everolimus. Patients may be allowed to continue 
combination therap y with Sandostatin LARÂ®Depot if they are currently  receiving this 
combination therap y on the parent pro tocol and at the discretion of the investigator.
This study  will not include a screening phase as patients will transfer directly  from the parent 
study  and will commence with everolimus as soon as they are consented and meet the 
inclusion criteria of the r oll-over protocol.
2.3 Rationale for dose and regimen selection
Everolimus will be provided as 2.5 mg, 5 mg or 10 mg tablets. At the time of transition to the 
roll-over study , the starting dose of everolimus should be the same as the last dose that was 

Novartis Confidentia l Page 17
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
given in the parent study . Dose modification thereafter may be done at the discretion of the 
investigator based upon what is in the patientâ€™s best interest.  
The roll-over protocol is designed to provide continued treatment with everolimus 
monotherap y to patient s. If patients are receiving treatment of everolimus in combination with 
other approved therapies, they can participate in the roll-over study  but it is not intended for 
combination with unapproved or experimental treatments.  Therefore, for patients recei ving 
everolimus in combination with Sandostatin LARÂ®Depot, Sandostatin LARÂ®Depot will be 
provided by Novartis or by the investigational site considering local regulations. At the time 
of transition to the roll -over study , the starting dose of Sandostatin LARÂ®Depot should be the 
same as the last dose that was given in the parent study .
2.4 Rationale for choice of combination drugs 
Patients may be allowed to continue combination therap y with everolimus and Sandostatin 
LARÂ®Depot at the discretion of the investigator if they are currently  receiving this 
combination therap y on the parent protocol and are deriving benefit as defined in the criteria 
of the parent protocol.
2.5 Rationale for choice of comparators drugs
Not applicabl e.
2.6 Risks & Benefits
Postmenopausal women with hormone receptor- positive advanced breast 
cancer in combination with aromatase inhibitors, after prior endocrine therapy
Overall, everolimus + exemestane is considered to have a positive benefit -risk profile for 
postmenopausal women with hormone receptor -positive advanced breast cancer in 
combination with an aromatase inhibitor, after prior endocrine therapy ; the benefits of therapy  
with everolimus + exemestane outweigh an y potential risks.
Advanced neuroendocrine tumors of pancreatic origin 
Everolimus has a positive benefit -risk profile for patients with advanced pancreatic
neuroendocrine tumors (pNET). Prior study  results support the use of everolimus for the 
treatment of patients with advanced pNET. Results provided evidence that everolimus, in 
combination with octreotide depot, improved PFS in patients with advanced carcinoid tumors. 
The primary  endpoint of the study  was not met. More data is needed to better assess the 
benefit -risk of everolimus in this pa tient population.
Renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib
Overall, everolimus is considered to have a positive benefit -risk profile for patients with 
advanced renal cell carcinoma after treatment failure with sunit inib or sorafenib. The benefits 
of therap y with everolimus outweigh an y potential risks.

Novartis Confidentia l Page 18
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3 -1below.

Novartis Confidential Page 19
Amended Protocol Version 01 Clean Protocol No. C RAD001C2X01B
Table 3-1 Objectives and related endpoints
Objective Endpoint Analysis
Primary
To evaluate long term safety data Frequenc y and severity of AEs/SAEs Refer to Section 10.4
Secondary
To evaluate clinical benefit as assessed by the 
investigatorProportion of patients with clinical benefit as 
assessed by the investigator at scheduled visitsRefer to Section 10.5

Novartis Confidential Page 20
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
4 Study  design
4.1 Description of study  design
This is a multi -center, open label study  to better characterize the long-term safet yof 
everolimus inpatients currentl y being treated in a Novartis -sponsored OGD&GMA study and
who are not progressing on the current study  treatment as judged by the investigator .Parent 
studies eligible to participate in the roll-over study  will be decided by Novartis. Investigator 
initiated trials (IIT) will not be included.
There will be no s creening period for this study . Eligible patients can start their treatment with 
everolimus as soon as they enter the study . All patients must report to the study  site for their 
first visit and commence study  participation. At that time, a quarterl y supply of everolimus 
may be dispensed to the patient /or as per local practice .  
Patients must return to the study  center at least on a quarterly basis (Â± 1 week ) for resuppl y of 
study  medication.  Drug dispensing information and adverse events will be collected. The 
patient may return to the clinic at any given time as per standard of care or treating physician 
recommendation ;however only the quarterl ystudy  visits will be recorded. Study  medication 
dispensed will be recorded on the dose admin istration page. 
All reported adverse events and serious adverse events will be collected thr oughout the stud y.
Patients will continue to be treated in the roll -over protocol until they  are no longer benefiting 
from their everolimus treatment as judged by the investigator (disease progression), they 
develop unacceptable toxicities, they withdraw consent, they are non-compliant to the 
protocol, the investigator feels it is no longer in the patientâ€™s best interest to continue 
everolimus therap y or the patient dies, whichever comes first. At every quarterl y visit, the 
investigator is required to confirm that the patient continues to have clinical benefit and may 
continue receiving stud y treatment.
A patient will reach the end of study  when everolimus treatment is permanently  discontinued.
The study  is expected to remain open for 10 years or until such time that enrolled patients no 
longer need treatment with everolimus or are able to obtain commercial supply  according to 
local regulations for their medical condi tion.
Figure 4-1 Study  design
*Note: The starting everolimus (and Sandostatin LARÂ®Depot, if applicable) dose will be the same as 
the last dose received in the parent study.Parent Novartis 
Oncology CD&M A 
study:
Everolimus
(tolerabl e effective dose)Roll-over study :
*Everol imus
(at assign ed dose)End of roll-over study :
Everolimus is 
perm anentl y 
discontinued 

Novartis Confidential Page 21
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
4.2 Timing of interim analy ses and design adaptations
Not applicable.
4.3 Definition of end of study
End of study  is defined as either 10 years duration or when all patient s on this study  have 
permanentl y discontinued everolimus treatment and the end of treatment visit has been 
performed for each patient, whichever comes earlier.
4.4 Early study  termination
The study  is expected to remain open for 10 years or until such time that enrolled patients no 
longer need treatment with everolimus or are able to obtain commercial supply  according to 
local regulations for their medical condition.
The study  can be terminated at any  time for any  reason by  Novartis. Should this be necessary, 
the prematurel y withdrawn patient should be seen as soon as possible. The investigator may 
be informed of additional procedures to be followed in order to ensure that adequate 
consideration is given to the protection of the patientâ€™s interests. The investig ator will be 
responsible for informing I RBs and/or ECs of the earl y termination of the trial.
5 Population
5.1 Patient population
The investigator or designee must ensure that only patients who meet all the following 
inclusion and none of the exclusion criteria are offered treatment in the study.
5.2 Inclusion criteria
Patients eligible for inclusion in this study  have to meet all of the following criteria:
1.Patient is currently
 enrolled in a Novartis -sponsored, Oncology  Global Development & 
Global Medical Affairs ( OGD&GMA ) study  receiving everolimus or everolimus plus 
Sandostatin L ARÂ®Depot and has fulfilled all their requirements in the parent study .
2.Patient is currently  benefiting from the treatment with everolimus, as determined by  the 
guidelines of the parent prot ocol. 
3.Patient has demonstrated compliance, as assessed by  the investigator, with the parent 
study  protocol requirements.
4.Willingness and ability  to comply  with scheduled visits and treatment plans.
5.Written informed consent obtained prior to enrolling into the roll -over study .
ï‚·If consent cannot be expressed in writing, it must be formall y documented and 
witnessed, ideall y via an independent trusted witness.

Novartis Confidential Page 22
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
5.3 Exclusion criteria
Patients eligible for this study  must not meet anyof the following criteria:
1.Patient has been permanently  discontinued from everolimus study  treatment in the parent 
study .
2. Patients who are receiving everolimus in combination with unapproved or experimental 
treatments.
3.Sexually  active males, unless they  use a condom during intercour se while taking drug and 
for 8 weeks after stopping stud y medication. Males also should not father a child in this 
period. A condom is required to be used also b y vasectomized men in order to prevent 
delivery  of the drug via seminal fluid.
4.Pregnant or nurs ing (lactating) women, where pregnancy  is defined as the state of a female 
after conception and until the termination of gestation, confirmed by  a positive hCG 
laboratory  test.
5.Women of child- bearing potential, defined as all women physiologicall y capable of 
becoming pregnant, unless they are using highly  effective methods of contraception 
during dosing and for 8 weeks after stopping study treatment. 
ï‚·Women are considered post -menopausal and not of child- bearing potential if they  
have had 12 months of natur al (spontaneous) amenorrhea with an appropriate clinical 
profile (e.g. age appropriate, history  of vasomotor sy mptoms) or have had surgical 
bilateral oophorectomy  (with or without hy sterectomy ) or tubal ligation at least six 
weeks prior to randomization. I n the case of oophorectom y alone, onl y when the 
reproductive status of the woman has been confirmed by  follow up hormone level 
assessment is she considered not of child-bearing potential
Highly effective contraception methods include:
ï‚·Total abstinence: Whe n this is in line with the preferred and usual lifest yle of the 
subject. [Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation 
methods) and withdrawal are not accept able methods of contraception].
ï‚·Female Sterilization: Have had sur gical bilateral oophorectom y (with or without 
hysterectom y) or tubal ligation at least six weeks before taking stud y treatment. I n 
case of oophorectom y alone, only  when the reproductive status of the woman has 
been confirmed b y follow up hormone level asse ssment.
ï‚·Male partner sterilization (at least 6 months prior to enrolling ).[For female study  
subjects, the vasectomized male partner should be the sole partner for that patient] 
ï‚·Use of oral, injected or implanted hormonal methods of contraception or place ment of 
an intrauterine device (IUD) or intrauterine s ystem (IUS), or other forms of hormonal 
contraception that have comparable efficacy  (failure rate <1%), for example hormone 
vaginal ring or transdermal hormone contraception.
ï‚·In case of use of oral contraception, women should have been stable on the same pill 
before taking stud y treatment.
If a stud y patient becomes pregnant or suspects being pregnant during the study  or within 30 
days after the final dose of everolimus, the investigator needs to be informed immediately  
and ongoing stud y treatment with everolimus has to be stopped immediately.

Novartis Confidential Page 23
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
6 Treatment
6.1 Stud y treatment
Study  treatment and investigational treatment refer to everolimus.
6.1.1 Dosing regimen
Table 6-1 Dose and treatment schedule
Study treatments Pharmaceutical form and 
route of administrationDose Frequency and/or 
Regimen
RAD001/everolimus Tablet for oral use 2.5 â€“10 mg/day Daily
Everolimus will be provided as 2.5 mg, 5 mg or 10 mg tablets. The investigational treatment 
is to be stored in a secure locked area while under the responsibility  of the investigator. 
Receipt and dispensing of investigational treatment must be recorded by an authorized person 
at the investigatorâ€™s site. Everolimus for the roll-over study  can be provided as local 
commercial material or global supply  where appropriate. 
At the time of transition to the roll-over study , the starting dose of everolimus should be the 
same as the last dose that was given in the parent study . Dose modification thereafter may be 
done at the discretion of the investigator based upon what is in the patientâ€™s best interest.  
Patients will be instructed to take everolimus orally  with aglass of water, once daily at the 
same time each day, either consistentl y with food or consistentl y without food. Dietary  habits 
at the time of enrolling in the study  from the parent study  should be kept as consistent as 
possible throughout the study .  The tablet should be swallowed as a whole and should not be 
chewed or crushed. 
Please refer to the current everolimus IB and Section 6.3for further important information on 
potential dosing precautions regarding concomitant medication interaction with cytochrome 
p450, p- glycoprotein, and CYP3A4 and the recommended dosing guidance.
6.1.1.1 Dosing regimen for combination therapy  treatment
The roll-over protocol is designed to provide continued treatment with evero limus 
monotherap y to patients. If patients are receiving treatment of everolimus in combination with 
other approved therapies, they can participate in the roll-over study , but it is not intended for 
combination with unapproved or experimental treatments.  Therefore, for patients 
receiving 
everolimus in combination with Sandostatin LARÂ®Depot on the parent protocol, Sandostatin 
LARÂ®Depot will continue to be provided by Novartis or by the investigational site 
considering local regulations.  At the time of tr ansition to the roll -over study , the starting dose 
of Sandostatin LARÂ®Depot should be the same as the last dose that was given in the parent 
study .
Table 6-2 Combination the rapy  dose and treatment schedule
Study treatments Pharmaceutical form 
and route of 
administrationDose Frequency and/or 
Regimen

Novartis Confidential Page 24
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
Study treatments Pharmaceutical form 
and route of 
administrationDose Frequency and/or 
Regimen
Sandostatin LARÂ®(if 
applicable)Intramuscular injection At discretion of treating 
physician At discretion of treating 
physician
6.1.2 Ancillary  treatments
Not applicable.
6.1.3 Rescue medication 
Not applicable.
6.1.4 Guidelines for continuation of treatment
The starting dose of everolimus should be the same as the last dose that was given in the 
parent everolimus study. Following the starting dose, patientâ€™s may have their dose of 
everolimus (2.5-10 mg/day) adjusted based on the investigatorâ€™s judgment of what dose is in 
the patientâ€™s best interest.
6.1.5 Treatment duration
Patients will continue to be treated in the roll -over protocol until they are no longer benefiting 
from their everolimus treatment as judged by the investigator (disease progression), they 
develop unacceptable toxicities, they withdraw consent, they are non-compliant to the 
protocol, the investigator feels it is no longer in the patientâ€™s best interest to continue 
everolimus therap y or the patient dies, whichever comes first. At every quarterl yvisit the 
investigator is required to confirm that the patient continues to have clinical benefit and may 
continue receiving study treatment. A patient will reach the end of the roll-over study  when 
everolimus treatment is permanentl y discontinued.
The study  is expected to remain open for 10 years or until such time that enrolled patients no 
longer need treatment with everolimus or are able to obtain commercial supply  according to 
local regulations for their medical condition.
6.2 Dose escalation guidelines
Not applicable.
6.3 Dose modifications 
6.3.1 Dose modification and dose delay
Patients will begin the roll-over study  at the same dose as the last dose administered in the 
parent protocol. Dose adjustments are permitted to allow the patient to continue the study 
treatment at the investigatorâ€™s discretion. Dose modifications may be applied
at the 
investigatorâ€™s discretion in conjunction with the most current IB.
Everolimus and Sandostatin LAR DepotÂ®dose changes must be recorded on the Dosage 
Administration Record eCRFs.

Novartis Confidential Page 25
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
6.3.2 Follow -up for toxicities
Patients whose treatment is interrupted or permanently  discontinued due to an adverse event 
or clinically  significant laboratory  value, should be followed upat least once a week (or more 
frequentl y if clinicall y indicated) for 4 weeks, and subsequentl y at approximately  4-week 
intervals, until resolution or stabilization of the event, whichever comes first.
Appropriate clinical experts such as ophthalmologist, endocrinologist, dermatologist, 
psychiatrists etc. should be consulted as deemed necessary . Patients must be followed for 
adverse events and serious adverse events for 30 day s following the last dose of everolimus.
6.3.2.1 Follow up on potential drug -induced live r injury (DILI) cases
Patients with transaminase increase combined with TBIL increase may be indicative of 
potential DILI, and should be considered as clinically  important events. 
The threshold for potential DILI may depend on the patientâ€™s baseline AST/A LT and TBIL 
value; patients meeting any of the following criteria will require further follow -up as outlined 
below:
ï‚·For patients with normal ALT and AST and TBIL value at baseline: AST or AL T > 3.0 x 
ULN combined with TBIL > 2.0 x UL N 
ï‚·For patients with el evated AST or ALT or TBIL value at baseline: [AST or AL T > 2 x 
baseline AND > 3.0 x ULN] OR [AST or ALT > 8.0 x ULN], combined with [TBIL > 2 x 
baseline AND > 2.0 x ULN]
Medical review needs to ensure that liver test elevations are not caused by  cholestasi s, defined 
as ALP elevation > 2.0 x ULN with R value < 2 in patients without bone metastasis, or 
elevation of ALP liver fraction in patients with bone metastasis.
Note: (The R value is calculated by  dividing the ALT by  the ALP, using multiples of the ULN 
for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to 
cholestatic (R â‰¤ 2), hepatocellular (R â‰¥ 5), or mixed (R >2 and < 5) liver injury ).
In the absence of cholestasis, these patients should be immediately  discontinu ed from study 
drug treatment, and repeat LFT testing as soon as possible, preferably  within 48 hours from 
the awareness of the abnormal results. The evaluation should include laboratory  tests, detailed 
history , physical assessment and the possibility of liver metastasis or new liver lesions, 
obstructions/compressions, etc. 
1.Laboratory  tests should include ALT, AST, albumin, creatine kinase, total bilirubin, direct 
and indirect bilirubin, GGT, prothrombin time (PT)/INR and alkaline phosphatase. 
2.A detailed history , including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumption, history  of any  pre-existing liver 
conditions or risk factors, should be collected. 
3.Further testing for acute hepatitis A, B, C or E infection and liver imaging (e.g. biliary  
tract) may  be warranted. 
4.Obtain PK sample, as close as possible to last dose of study  drug, if PK analy sis is 
performed in the stud y. 

Novartis Confidential Page 26
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
5.Additional testing for other hepatotropic viral infection (CMV, EBV or HSV), 
autoimmune hepatitis or liver biopsy  may  be considered as clinically  indicated or after 
consultation with specialist/hepatologist. 
All cases confirmed on repeat testing meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified should be considered as â€œmedically 
significantâ€, thus, met the definition of SAE (Section 8.2.1) and reported as SAE using the 
term â€œpotential drug -induced liver injury â€. All events should be followed up with the outcome 
clearl y documented.
6.3.3 Anticipated risks and safety  concerns of the study  drug
It is anticipated that the patients entering the roll-over protocol have tolerated everolimus 
treatment and are anticipated to benef it from continued treatment. 
Guidelines and recommendations for the management of specific everolimus study  drug 
induced toxicities (hypergly cemia, hyperlipidemia, stomatitis, infectious 
pneumonitis, 
reactivation of Hepatitis B and C) are provided in the current everolimus Investigator 
Brochure.
6.4 Concomitant medications
6.4.1 Permitted concomitant therapy
In general, concomitant medications/therapies deemed necessary  for the supportive care of the 
patient is permitted.
6.4.2 Permitted concomitant therapy  requiring caution and/or action
Everolimus is metabolized by CYP3A4 in the liver and to some extent in the intestinal wall. 
Therefore, the following are recommended:
ï‚·Co-administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, 
ritonavir) or P-glycoprotein (PgP) inhibitor should be avoided.
ï‚·Co-administration with moderate CYP3A4 inhibitors (e.g., ery thromy cin, fluconazole) or 
PgP inhibitors should be used with caution. If a patient requires co -administration of 
moderate CYP3A4 inhibitors or Pg P inhibitors, reduce the dose of study  drug to half the 
currentl y used dose. Additional dose reductions to every other day may be required to 
manage toxicities. I f the inhibitor is discontinued, the study  drug dose should be returned 
to the dose used prior to initiation of the moderate CYP3A4/PgP inhibitor.
ï‚·Seville orange, star fruit, grapefruit and their juices affect P450 and PgP activity . 
Concomitant use should be avoided.
ï‚·Co-administration with strong inducers of CYP3A4 should be avoided. If a patient 
requires co -administration of strong CYP3A4 inducers (i.e., pheny toin, carbamazepine, 
rifampin, rifabutin, phenobarbital, St. Johnâ€™s wort), an increase in the dose of study  drug 
up to twice the currentl y used daily  dose should be considered, 5mg increments. Enzy me 
induction usually  occurs within 7 -10 day s; therefore study  drug dose should be increased 
by one increment 7 day s after the start of the inducer therapy . If no safety  concerns are 
seen within the next 7 days, the dose can be increased again one addi tional increment up 

Novartis Confidential Page 27
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
to a maximum of twice the daily  dose used prior to initiation of the strong CYP3A4 
inducer.
ï‚·This dose adjustment of study  drug is intended to achieve similar AUC to the range 
observed without inducers. However, there are no clinical dat a with this dose adjustment 
in patients receiving strong CYP3A4 inducers. If the strong inducer is discontinued the 
study  drug dose should be returned to the dose used prior to initiation of the strong 
CYP3A4/PgP inducer.
Please refer to Table 6-3listing relevant inducers and inhibitors of CYP3A and to Table 6-4
for a list of relevant substrates, inducers, and inhibitors of PgP.   Please refer to the most recent 
Investigatorâ€™s Brochure for a complete list.
Table 6
-3 Clinically  relevant drug interactions: inducers, and inhibitors of 
isoenzy me CYP3A
Inducers
Strong inducer s:
avasimibe, carbamazepine, mitotane, phenobarbital, phenytoin, rifabutin, rifampin (rifampicin), St. John's wort 
(hypericum perforatum)
Moderate inducers:
bosentan, efavirenz, etravirine, genistein, modafinil, nafcillin, ritonavir, [talviraline], thiorid azine, tipranavir
Weak inducers:
amprenavir, aprepitant, armodafinil (R-modafinil), bexarotene, clobazam, danshen, dexamethasone, Echinacea, 
garlic (allium sativum), gingko (ginkgo biloba), glycyrrhizin, methylprednisolone, nevirapine, oxcarbazepine, 
piogl itazone, prednisone, [pleconaril], primidone, raltegravir, rufinamide, sorafenib, telaprevir, terbinafine, 
topiramate, [troglitazone] , vinblastine
Inhibitors
Strong inhibitors:
boceprevir , clarithromycin, cobicistat, conivaptan, elvitegravir, indinavir, itraconazole, ketoconazole, lopinavir, 
mibefradil, nefazodone, nelfinavir, posaconazole ( Krishna et al 2009 ), ritonavir, saquinavir, telaprevir , 
telithromycin, tipranavir, troleandamycin, voriconazole
Moderate inhibitors:
Amprenavir, aprepitant, atazanavir, casopitant, cimetidine, ciprofloxacin, cyclosporine, darunavir, diltiazem, 
dronedarone, erythromycin, fluconazole, fosamprenavir, grapefruit juice (citrus parasidi fruit juice), imatinib, 
schisandra sphenanthera, tofisopam, verapamil

Novartis Confidential Page 28
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
Table 6-4 Clinically  relevant drug interactions: substrates, inducers, inhibitors 
of PgP and PgP/CYP3A dual inhibitors
Substrates
colchicine, digoxin, fexofenadine, indinavir, paclitaxel, talinolol, topotecan, vincristine, everolimus
Inducers
rifampin, St Johnâ€™s wort
PgP Inhibitors and PgP/CYP3A Dual Inhibitors
amiodarone, azithromycin, captopril, carvedilol, clarithromycin, coni vaptan, diltiazem, dronedarone, elacridar, 
erythromycin, felodipine, fexofenadine, fluvoxamine, ginkgo (ginkgo biloba), indinavir, itraconazole, lopinavir, 
mibefradil, milk thistle (silybum marianum), nelfinavir, nifedipine, nitrendipine, paroxetine, querc etin, quinidine, 
ranolazine, rifampin, ritonavir, saquinavir, Schisandra chinensis, St Johnâ€™s wort (hypericum perforatum), talinolol, 
Telaprevir, telmisartan, ticagrelor, tipranavir, tolvaptan, valspodar, verapamil
Reference: Internal Clinical Pharmacolog y Drug -drug interaction (DDI) memo, updated 29 -Oct-2012 which 
summarizes DDI data from three sources including the FDAâ€™s â€œGuidance for Industry, Drug Interaction Studiesâ€, 
the University of Washingtonâ€™s Drug Interaction Database, and Indiana University Sch ool of Medicine's Drug 
Interaction Table.
Vaccinations
The use of live vaccines and close contact with those who have received live vaccines should 
be avoided during treatment with everolimus. Examples of live vaccines are: intranasal 
influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a 
typhoid vaccines.
For further details refer to the current everolimus Investigatorâ€™s Brochure.
6.4.3 Prohibited concomitant therapy
Treatment with systemic anticancer agents (chemotherapy , hormone therapy , targeted or 
biologic agents) other than everolimus is not permitted until disease progression is 
documented and everolimus is permanently  discontinued.
6.4.4 Use of Bisphosphonates (or other concomitant agents)
Not applicable.
6.5 Patient numbering, treatment assignment or randomization
6.5.1 Patient numbering
Each patient is identified in the study  by a Subject Number (Subject No.), that is assigned 
when the patient is first enrolled in the roll -over study  and is retained as the primary  identifier 
for the patient throughout his/her entire participation in the trial. The Subject No. consists of 
the Center Number (Center No.) (as assigned by Novartis to the investigative site) with a 
sequential patient number suffixed to it, so that each subject is numbered uniquely  across the 
entire database. Upon signing the informed consent form, the patient is assigned to the next 
sequential Subject No. available to the investigator through the Oracle Clinical RD C interface 
(OCRDC). 

Novartis Confidential Page 29
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
Additionally  an eCRF will be completed that identifies the patient by gender and date of birth 
and previous study, site/center and subject number.
6.5.2 Treatment assignment or randomization
All consented patients who meet all the inclusion criteria and none of the exclusion criteria 
are eligible to receive everolimus.
6.5.3 Treatment blinding
Not applicable.
6.6 Stud y drug preparation and dispensation
The investigator or responsible site personnel must instruct the patient or caregiver to take the 
study drugs as per protocol. Study  drug(s) will be dispensed to the patient by authorized site 
personnel only. All everolimus dosages prescribed to the patient and all dose changes during 
the study  must be recorded on the Everolimus Dosage Administration Rec ord eCRF.
Table 6-5 Preparation and dispensin g
Study treatments Dispensing Preparation
Everolimus Blister packed tablets (2.5 â€“10 mg) including instructions for 
administration will be dispensed by study personnel on an 
outpatient basis.
Patients will be provided with an adequate supply of study 
treatment for self -administration at home until at least their next 
scheduled quarterly ( 12 weeks Â± 1 week ) study visit. 
If study drug is supplied by Novartis Drug Supply Management, 
the supply may be dispensed more frequently if required based 
on local practice or drug expiration date.Not applicable
6.6.1 Study treatment packaging and labeling
Everolimus for the roll-over study  can be provided where appropriate as local commercial 
material or as global open -label suppl y, packed and labeled under the responsibility  of 
Novartis Drug Supply  Management. Study  treatment labels will be in the local language and 
comply  with the legal requirements of each country . They  will include storage conditions for 
the drug but no information about the patient.
If everolimus is provided and labeled in-country , the locally -approved form and packaging of 
everolimus will be used.
Table 6-6 Packaging and labeling
Study treatments Packaging Labeling (and dosing frequency)
Everolimus Tablets in blisters * As per local requirements
* For centrally supplied medication. If everolimus is sourced and labeled in-country/locally, the locally-approved 
form, packaging and labeling of everolimus will be used.

Novartis Confidential Page 30
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
6.6.2 Drug supply  and storage
Study  treatments must be received by designated personnel at the study site, handled and 
stored safel y and properly , and kept in a secured location to which only the investigator and 
designated site personnel have access. Upon receipt, everolimus should be stored according to 
the instructions specified on the drug labels and in the I nvestigatorâ€™s Brochure. 
Table 6-7 Supply  and storage of study  treatment s
Study treatments Supply Storage
Everolimus Centrally or locally supplied by 
NovartisRefer to study treatment label or local product 
information
6.6.3 Study drug compliance and accountability
6.6.3.1 Study drug compliance
Compliance will be assessed by the investigator and/or study  personnel at each patient visit 
and information provided by the patient and/or caregiver will be captured in the Drug 
Accountability  Form and other relevant source documents.
6.6.3.2 Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  treatment in a drug accountability  log. Drug accou ntability  will be noted by the field 
monitor during site visits and at the completion of the study . Patients will be asked to return 
all unused study  treatment and packaging on a regular basis, at the end of the study  or at the 
time of study  treatment discontinuation.
6.6.3.3 Handling of other study  treatment
If the patient was receiving a combination therapy  with an approved, commerciall y available 
treatment with everolimus in the parent protocol, and is eligible for the roll-over study , this 
combination therap y will be allowed until the patient permanently  discontinues everolimus. 
All Sandostatin LARÂ®Depot dosages prescribed to the patient and all dose changes during the 
study  must be recorded on the Sandostatin Dosage Administration Record eCRF.
Dispensation, compliance and accountabilit y of any combination therap y administered to the 
patient is under the supervision and discretion of the investigator. Sandostatin LARÂ®Depot 
will be provided by Novartis or by the investigational site considering local regulation s. 
Sandostatin L ARÂ®Depot will be distributed in country -specific approved packaging.

Novartis Confidential Page 31
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
6.6.4 Disposal and destruction
At study  close-out, and, as appropriate during the course of the study , the investigator will 
return all used and unused study  treatment, packagi ng, drug labels, and a copy  of the 
completed drug accountability  logto the Novartis monitor or to the Novartis address provided 
in the investigator folder at each site.
The study  drug can only  be destro yed once the study  drug accountability  check has been done 
by the monitor. The study  drug can be destroy ed at the local Novartis facility  or by a third 
party , as appropriate.
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Table 7-1lists allof the assessments and indicates with an â€œXâ€, the visits when they are 
performed. A visit window of Â± 1 week is allowed. All data obtained from these assessments 
must be supported in the patientâ€™s source documentation.  
The table indicates in the â€œCategory â€ column which assessments produce data to be entered in 
the database (D) or documented at the site level in the source documents (S).

Novartis Confidential Page 32
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
Table 7-1 Visit evaluation schedul eCategoryProtocol 
reference
section
EnrolmentQuarterly (every 12 weeksÂ± 1 
week) visits during treatment 
phaseEnd of 
treatment (EoT)30 day safety
follow -up post last 
dose of study drug/
End of Study
Visit Number 1 Visit 2, 3, 4 etc. 777
Obtain informed consent D 7.1.2 x
Patie ntâ€™s previous study, site, and 
subject numberD 7.1.2.3 x
Demography D 7.1.2.3 x
Relevant medical history/current 
medical conditionsD 7.1.2.3 x
Inclusion/exclusion criteria D 5.2/5.3 x
Serum pregnanc y testing D 7.2.2 x x
Urine pregnancy testing S/D 7.2.2 monthly 
Adverse events and Serious 
adverse eventsD 8.1/8.2 x continuous x x
Everolimus dosing administration D 6.6 x continuous
Sandostatin LARÂ®  Depot dosing 
administration (if applicable)D 6.6 x continuous
Confirmation of Clinical Benefit from 
Study TreatmentD 6.1.5 x continuous
End of study treatment D 7.1.5 x
Study evaluation completion D 7.1.5 x

Novartis Confidential Page 33
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
7.1.1 Molecular pre -screening
Not applicable.
7.1.2 Screening
At the enrollment visit the patient will complete a written informed consent . There will be no 
screening period for this study . Once consented, patie nts will be evaluated for eligibility  via 
the inclusion and exclusion criteria.
7.1.2.1 Eligibility  screening 
Not applicable.
7.1.2.2 Information to be collected on screening failures
Not applicable.
7.1.2.3 Patient demographics and other baseline characteristics
For patients that are eligible to participate in this roll-over study , the patientsâ€™ gender, date of 
birth, previous study , site/center and subject number , and relevant medical history  will be 
collected.
7.1.3 Run- in period 
Not applicable.
7.1.4 Treatment period
The starting dose o f everolimus on this roll -over protocol will be the same as the last dose that 
was given in the parent everolimus study . A 3 month supply  of everolimus will be dispensed 
to the patient, or what is allowed according to local practice/regulations.
Patients must return to the study  center on a quarterly  basis (12 weeks Â± 1 week ) for resuppl y 
of study  medication at which time drug dispensing information and adverse event information 
will be collected. At this time the dose of everolimus is based on the investigatorâ€™s judgment. 
At every  quarterl y visit, the investigator is required to confirm that the patient continues to 
have clinical benefit and may  conti nue treatment with study  drug .
The study  is expected to remain open for 10 years or until such time that enrolled patients no 
longer need treatment with everolimus or are able to obtain commercial supply  according to 
local regulations for their medical condition.
7.1.5 Discontinuation of study treatment
Patients will continue to be treated until they are no longer benefiting from everolimus 
treatment, develop unacceptable toxicities, withdraw consent, are non-compliant to the 
protocol, or the patient dies, whichever comes first.
At the time the patient discontinues study  treatment, a visit should be scheduled as soon as 
possible, at which time the End of Treatment visit will be performed. End of Treatment 

Novartis Confidential Page 34
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
information will be completed in the eCRF giving the date and reason for stopping the study 
treatment (se e Section 7.1.5.1).
At a minimum, all patients who discontinue study  treatment, including those who refuse to 
return for a final visit, will be contacted for the required safet y evaluation during the 30 days 
following the last dose of study  treatment. The completion of the Study  Evaluation 
Completion eCRF page is required any  time a patient discontinues from the study  and must be 
completed 30 day s after the end of treatment.
Patients who discontinue study treatment should be considered withdrawn from the study  after 
the final visit assessments are performed or when it is clear that the patient will not return for 
these assessments.
If a study  withdrawal occurs, or if the patient fails to return for visits, the investigator must 
determine the primary  reason for a patientâ€™s withdrawal from the study  and record this 
information on the appropriate eCRF page.
A patient will reach the end of study  when everolimus treatment is permanently discontinued 
and there wi ll be nofurther follow- up study  visits.
7.1.5.1 Withdrawal of consent
Patients may voluntaril y withdraw consent toparticipate inthestudy foranyreason at any 
time.Withdrawal of consent occurs only when apatient does notwant toparticipateinthe 
study anylonger, anddoes notwant anyfurther visits orassess ments, anddoes notwant any 
further study related contact.
Novartis will continue toretain anduseallresearch results thathave alread ybeen collected 
forthestudy evaluation. Allbiological samplesthat have already beencollected maybe 
retained andanalyzed
atalater date (or as required by local regulations).
Ifa patient
withdraws consent, theinvestigator should makea reasonable effort (e.g. telephone,
e-mail, lette r) to understand t he pri mary reason for this de c ision and rec ord this in f orm ation.
Everolimus must be discontinued andnofurther assess mentsconducted.
Further attempts toc
ontact thepatie ntarenot allowed unless safety findings require 
communication or follow up.
Patients may be withdrawn from the study  if an y of the following occur:
1.Adverse event(s).
2. Subject withdrew consent.
3.Lost to follow -up.
4. Administrative problems.
5.Death.
6.Disease progression.
7.Treatment duration completed as per protocol.
8. Protocol deviation
9.Sponsor deci sion

Novartis Confidential Page 35
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
7.1.5.2 Replacement policy  
Not applicable.
7.1.6 Follow up for safety  evaluations 
All patients must be followed up for safety  evaluations for 30 days after the last dose of 
everolimus. At the end of this period, the investigator should contact the patient to inquire 
about any adverse events or serious adverse events observed during this period. This could be 
done via a phone contact. Following this there are nofurther follow -up study  visits.
7.1.7 Lost to fo llow- up
Forpatie ntswhose status is unclear because they failtoappear forstudy  visits without stating 
anintention towithdraw consent, theinvestigator should show "due diligence" bycontacting 
thepatient, family orfamily physician asa
greed intheinfor medconsent andbydocumenting 
inthesource docu ments steps taken tocontact thepatient, e.g. dates oftelephone calls, 
regis
tered letters,etc.Apatie ntsho uldnot be considered losttofollow -upuntil duediligence 
hasbeen completed. Patients losttofollow upshould berecorded assuch ontheappropriate 
Disposition CRF.
7.2 Assessment ty pes
7.2.1 Efficacy  assessments
At every  quarterl y visit, the investigator is required to confirm that the patient continues to 
have clinical benefit and may  continue receiving study  treatment.
7.2.2 Safety  and tolerability ass essments
Safety  will be monitored by collecting Adverse Events throughout the study  on a continuous 
basis. See Section 8.
Women of child- bearing potential must complete the following pregnancy  tests:
ï‚·Baseline/Enrollment -serum pregnancy  test done locally
ï‚·Every  4 weeks during treatment - urine pregnancy test. Can be administered at patientâ€™s 
home.
ï‚·End of Treatment visit -serum pregnancy  test done locall y
Women of child- bearing potential who administer urine pregnancy  testing at home should 
complete a simple diary  with the dates and the outcome of the urine pregnancy  test while on 
study  treatment. In case of a positive pregnancy  test, the instructions in Section 8.4should be 
followed.
7.2.3
Pharmacokinetics
Not applicable.
7.2.4 Biomarkers
Not applicable.

Novartis Confidential Page 36
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
7.2.5 Resource utilization
Not applicable.
7.2.6 Patient reported outcomes
Not applicable.
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event isdefined as the appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s), or medical condition(s) that occur after patientâ€™s signed 
informed consent has been obtained.
Adverse events of special interest as noted in Section 8.1.3 will be reported as serious adverse 
events.
Abnormal laboratory  values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are conside red clinically  significant, 
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Any ongoing adverse events from the parent study  will be captured as medica l history  in the 
roll-over database . Any AEthat begins (or worsens) after signing of the informed consent for 
the rollover and during the 30-day (or 28 - day) safety  follow up period defined in the parent 
protocol should be reported in both clinical databas es.
Adverse event monitoring should be continued for at least 30 following the last dose of study  
treatment. Adverse events (including lab abnormalities that constitute AEs) should be 
described using a diagnosis whenever possible, rather than individual underly ing signs and 
symptoms. When a clear diagnosis cannot be identified, each sign or symptom should be 
reported as a separate Adverse Event.
Adverse events will be assessed according to the current version of the 
Common Terminology 
Criteria for Adverse Events (CTCAE) .If CTCAE grading does not exist for an adverse event, 
the severity  of mild, moderate, severe, and life-threatening, corresponding toGrades 1 - 4, 
will be used. CTCAE Grade 5 (death) will not be used in this study ; rather , information about 
deaths will be collected on the EOT page.
The occurrence of adverse events should be sought by  non-directive questioning of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study . Adverse events also may be detected when they are volunteered by the patient 
(subject) during the screening process or between visits, or through physical examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be 
evaluated to d etermine:

Novartis Confidential Page 37
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
1.The severit y grade (CTCAE Grade 1 -4)
2.Its duration (Start and end dates)
3.Its relationship to the study  treatment (reasonable possibility  that AE is related: No, Yes)
4.Action taken with respect to study  or investigational treatment (none, dose adjus ted, 
temporaril y interrupted, permanentl y discontinued, unknown, not applicable)
5.Whether medication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y)
6.Whether it is serious, where a serious adverse ev ent (SAE) is defined as in Section 8.2.1
If the event worsens the event should be reported a second time in the CRF noting the start 
date when the event worsens in toxicity . For grade 3 and 4 adverse events only, if 
improvement to a lower grade is determined a new entry  for this event should be reported in 
the CRF noting the start date when the event improved from having been Grade 3 or Grade 4.  
All adverse events should be treated appropriately . If a conc omitant medication or non-drug 
therap y is given, this action should be recorded on the Adverse Event CRF.
Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, and assessment should be made at each visit (or more frequently , if 
necessary ) of any changes in severit y, the suspected relationship to the study  treatment, the 
interventions required to treat it, and the outcome.
Progression of malignancy  (including fatal outcomes), if documented by useof appropriate 
method (for example, as per RECIST criteria for solid tumors or 
as per Cheson's guidelines 
for hematological malignancies), should not be reported as a serious adverse event.
Adverse events separate from the progression of malignancy  (examp le, deep vein thrombosis 
at the time of progression or hemopty sis concurrent with finding of disease progression) will 
be reported as per usual guidelines used for such events with proper attribution regarding 
relatedness to the drug.
8.1.2 Laboratory  test abnormalities
8.1.2.1 Definitions and reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therapy  or 
require changes in study  treatment), should be recorded on the Adverse Events CRF. 
Whenever possible, a diagnosis, rather than a symptom should be provided (e.g. anemia 
instead of low hemoglobin). Laboratory  abnormalities that meet the criteria for Adverse 
Events should be followed until they have returned to normal or an adequate explanation of 
the abnormality  is found. When an abnormal laboratory  or test result corresponds to a 
sign/sy mptom of an already  reported adverse event, it is not necessary  to separately  record the 
lab/test result as a n additional event.
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not 
automatically  indicate a SAE unless it meets the definition of serious as defined below and/or 
as per investigatorâ€™s discretion. A dose hold or medication for the lab abnormality  may be 

Novartis Confidential Page 38
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
required by the protocol in which case the lab abnormality  would still, by definition, be an 
adverse event and must be reported as su ch.
8.1.3 Adverse events of special interest 
Adverse events of special interest (AESI ) are defined as events (serious or non-serious) which 
are ones of scientific and medical concern specific to the sponsorâ€™s product or program, for 
which ongoing monitoring and rapid communication by the investigator to the sponsor may 
be appropriate. Such events may require further investigation in order to characterize and 
understand them. 
Adverse events of special interest are defined on the basis of an ongoing review of the safet y 
data. AESIs are discussed in det ail in the I nvestigator Brochure. 
In addition to all serious adverse events reported on a continuous basis throughout the study , 
the investigator should use the SAE form to report the following medically  significant 
potential risks noted in the Novartis R isk Management Plan for everolimus:
ï‚·Development toxicity
ï‚·Reproductive (teratogenicity ) toxicity
ï‚·Intestinal obstruction /ileus
ï‚·Male infertility
ï‚·Pancreatitis
ï‚·Cholelithiasis
ï‚·Muscle
-wasting/Muscle -loss
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event ( SAE) is defined as one of the following:
ï‚·Is fatal or life -threatening
ï‚·Results in persistent or significant disability /incapacity
ï‚·Constitutes a congenital anomaly /birth defect
ï‚·Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may  
require medical or surgical intervention to prevent one of the outcomes listed above
ï‚·Requires inpatient hospitalization or prolongation of existing hospitalization, 
ï‚·Note that hospitalizations for the following reasons should not be reported as seri ous 
adverse events:
ï‚·Routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition 
ï‚·Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not wo rsened since signing the informed consent
ï‚·Social reasons and respite care in the absence of any  deterioration in the patientâ€™s 
general condition

Novartis Confidential Page 39
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
ï‚·Note that treatment on an emergency outpatient basis that does not result in hospital 
admission and involves an event not fulfilling an y of the definitions of a SAE given above 
is not a serious adverse event
8.2.2 Reporting
To ensure patient safet y, every  SAE, regardless of suspected causality , occurring after the 
patient has provided informed consent and until at least 30 days after the patient has stopped 
study  treatment must be reported to Novartis within 24 hours of learning of its occurrence.
Any SAE that begins or worsens after signing of the informed consent for the roll-over and 
during the 30 -day (or 28 -day) safet y follow up period defined in the parent protocol should be 
reported as an adverse event in both clinical databases; however, only one SAE report will be 
sent to Novartis.
ï‚·Any SAE that begins or worsens during the 30- day (or 28- day) safet y follow up period
specified in the parent study , should have an SAE report submitted to Novartis with the 
parent protocol stud y number. 
ï‚·Any SAE that begins or worsens after the 30 -day (or 28- day)safety  follow -up period 
specified in the parent study , should have an SAE re port submitted to Novartis with the 
roll-over protocol stud y number.
Any additional information for the SAE 
including complications, progression of the initial 
SAE, and recurrent episodes must be reported as follow -up to the original episode within 24 
hours of the investigator receiving the follow -up information. An SAE occurring at a different 
time interval or otherwise considered completely  unrelated to a previously  reported one 
should be reported separately as a new event.
It is important to use the right SAE form with the correct protocol number for these two 
scenarios, to avoid confusion in SAE processing. For a patient already  on the roll-over 
protocol but follow up information is reported for the previous SAEs in the parent protocol, it 
must be clearl y labeled that this is for the parent protocol number.
Any SAEs experienced after the 30 day safety evaluation follow -up period should only be 
reported to Novartis if the investigator suspects a causal relationship to the study  treatment.  
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English, and submit the completed form within 24 hours to Novartis .  Detailed 
instructions regarding the SAE submission process 
and requirements for signatures are to be 
found in the investigator folder provided to each site.
Follow -up information is submitted in the same way as the original SAE Report . Each re-
occurrence, complication, or progression of the original event should be reported as a follow-
up to that event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued or withdrew from stud y participation.

Novartis Confidential Page 40
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
If the SAE is not previously  documented in the Investigatorâ€™s Brochure or Package Insert 
(new occurrence) and is thought to be related to the Novartis study  treatment, an oncology 
Novartis Drug Safet y and Epidemiology  (DS&E) department associate may urgently  require 
further information from the investigator for Health Authority  reporting. Novartis may  need to 
issue an Investigator Notification (IN), to inform all investigators involved in any study with 
the same drug that this SAE has been reported. Suspected Unexpected Serious Adverse 
Reactions (SUSARs) will be collected and reported to the competent authorities and relevant 
ethics committees in accordance with Directive 2001/20/EC or as per national regulatory 
requirements in participating countries.
8.3 Emergency  unblinding of treatment assignment
Not applicable.
8.4 Pregnancies
To ensure patient safet y, each pregnancy  occurring while the patient is on study  treatment 
must be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy 
should be followed up to determine outcome, including spontaneous or voluntary  termination, 
details of the birth, and the presence or absence of any  birth defects, congenital abnormalities, 
or maternal and/or newborn complications.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by the 
investigator to the oncology  Novartis Drug Safety  and Epidemiology  Department (DS&E). 
Pregnancy  follow -
up should be recorded on the same form and should include an assessment 
of the possible relationship to the study  treatment ofany pregnancy  outcome. Any SAE 
experienced during pregnancy  must be reported on the SAE Report Form.
Pregnancy  outcomes must be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother.
Preclinical data regarding reproductive toxicity  is described in the most recent Investigator 
Brochure. The potential reproductive risk for humans is unknown.  Women of childbearing 
potential should be advised to use highl y effective contraception methods while they are 
receiving everolimus and up to 8 weeks after treatment has been stopped.  If a pregnancy 
occurs while on stud y treatment, the newborn will be followed for at least 12 months.
8.5 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided Investigator
Brochure. Additional safety  information collected between IB updates will be communicated 
in the form of Investigator Notifications. This information will be included in the patient 
informed consent and should be discussed with the patient during the stud y as needed.
8.6 Data Monitoring Committee 
Not applicable. 

Novartis Confidential Page 41
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
8.7 Steering Committee
Not applicable. 
9 Data collection and management
9.1 Data confidentiality
Information about study  subjects will be kept confidential and managed under the applicable 
laws and regulations. Those regulations require a signed subject authorization informing the 
subject of the following:
ï‚·What protected health information (PHI) will be collected from subjects in this study
ï‚·Who will have access to that information and wh y
ï‚·Who will use or disclose that information
ï‚·The rights of a research subject to revoke their authorization for use of their PHI .
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability  to use all inf ormation collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g. has the 
subject experienced any new or worsened AEs) at the end of their scheduled study  period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participa nt 
information. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords, made available only to authorized personnel who 
have completed prerequisite training.
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigatorâ€™s meeting, Novartis 
personnel (or designated CRO) will review the protocol and CRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the CRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospital or clinic medical records) contai ning demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on CRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. Novartis monitoring standards require full verification 
for the presence of informed consent, adherence to the inclusion/exclusion criteria and 

Novartis Confidential Page 42
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
documentation of SAEs. Additional checks of the consistency  of the source data with the 
CRFs are performed according to the stud y-specific monitoring plan.
9.3 Data collection
For studies using Electronic Data Capture (EDC), the designated investigator staff will enter 
the data required by the protocol into the Electronic Case Report Forms (eCRF). The eCRFs 
have been built using fully  validated secure web-enable d software that conforms to 21 CFR 
Part 11 requirements, Investigator site staff will not be given access to the EDC system until 
they have been trained. Automatic validation programs check for data discrepancies in the 
eCRFs and, allow modification or ver ification of the entered data by  the investigator staff.
The Principal Investigator is responsible for assuring that the data entered in eCRFs is 
complete, accurate, and that entry  and updates are performed in a timely  manner.
9.4 Database management and quali ty control
For studies using eCRFs, Novartis personnel (or designated CRO) will review the data entered 
by investigational staff for completeness and accuracy . Electronic data queries stating the 
nature of the problem and requesting clarification will be created for discrepancies and 
missing values and sent to the investigational site via the EDC system. Designated 
investigator site staff are required to respond promptly  to queries and to make any necessary 
changes to the data.
At the conclusion of the study, the occurrence of any protocol violations will be determined. 
After these actions have been completed and the data has been verified to be complete and 
accurate, the database will be declared locked and made available for data analysis. 
Authorization isrequired prior to making any database changes to locked data, by joint 
written agreement between the Global Head of Biostatistics and Data Management and the 
Global Head of Clinical Development.
For EDC studies, after database lock, the investigator will receive a CD-ROM or paper copies 
of the patient data for archiving at the investigational site.
10 Statistical methods and data analy sis
10.1 Analysis sets
The following sets will be used for statistical analy sis and data reporting.
10.1.1 Full A nalysis Set
Not applicable.
10.1.2 Safety  set
The Safet y Set includes all patients who received at least one dose of study  medication after 
enrolling into the roll
-over protocol.

Novartis Confidential Page 43
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
10.1.3 Dose -determining analy sis set
Not applicable.
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline data characteristics will be summarized descriptivel y for the 
Safety  Set.
10.3 Treatments (study  treatment , compliance)
Dose administration data will be summarized using the Safet y Set.
10.4 Primary  objective
The primary  objective is to evaluate long term safet y as assessed by the occurrence of 
AEs/SAEs.
10.4.1 Variable
See Section 10.5.3.
10.4.2 Statistical hy pothesis, model, and method of analy sis
No hy pothesis will be tested.
10.4.3 Handling of missing values/censoring/discontinuations
Not applicable.
10.4.4 Supp ortive and Sensitivity analyses
No supportive anal ysis will be performed.
10.5 Secondary  objectives
10.5.1 Key secondary  objective(s)
Not applicable.
10.5.2 Other secondary  efficacy  objectives
The secondary  objective of the study  is to evaluate clinical benefit as assessed by the 
investigator.  Proportion of patients with clinical benefit as assessed by the investigator will 
be summarized at scheduled visits.
10.5.3 Safety  objectives
The assessment of safet y will be based mainly  on the frequency  of AEs and SAEs.
10.5.3.1 Analysis set and grouping for the analy ses
The overall observation period will be divided into two mutually  exclusive segments:

Novartis Confidential Page 44
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
1. on -treatment period: from day  of first dose of study  medica tion in the roll -over study  to 30
days after last dose of study  medication
2.post-treatm ent period: starting at day  30+1 after last dose of study  medication.
10.5.3.2 Adverse events (A Es)
Summary  tables for adverse events (AEs) will include only AEs that started or worsened 
during the on-treatment period, the treatment -emergent AEs. However, all safet y data 
(including those from the post-treatment periods) will be listed and those collected during the 
post-treatment period are to be flagged.
The incidence of treatment- emergent adverse events (new or worsening from baseline) will be 
summarized by system organ class and or preferred term, severit y (based on CTCAE grades), 
type of adverse event, relation to study  treatment.
Deaths reportable as SAEs and non-fatal serious adverse events will be listed by patient and 
tabulated b y type of adverse event.
10.5.3.3 Other safety  data
Not applicable.
10.5.3.4 Supportive analy ses for secondary
Not applicable.
10.5.3.5 Tolerability
Not applicable.
10.5.3.6 Pharmacokinetics
Not applicable.
10.6 Exploratory  objectives 
Not applicable.
10.7 Interim analy sis
Not applicable.
10.8 Sample size calculation
Not applicable.
10.9 Po
wer for anal ysis of key  secondary  variables
Not applicable.

Novartis Confidential Page 45
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibil ities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, the investigator is 
required to sign a protocol signature page confirming his/her agreement to conduct the study 
in accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to Novartis monitors, auditors, 
Novartis Clinical Quality  Assurance representatives, designated agents of Novartis, 
IRBs/IECs/REBs and regulatory  authorities as required.
11.3 Informed consent procedures
Eligible patients m ay only be included in the study  after providing written (witnessed, where 
required b y law or regulation), I RB/IEC/REB -approved informed consent 
Informed consent must be obtained before conducting any study -specific procedures (i.e. all 
of the procedures described in the protocol). The process of obtaining informed consent 
should be documented in the patient source documents. The date when a subjectâ€™s Informed 
Consent was actuall y obtained will be captured in their CRFs.
Novartis will provide to investigat ors, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by the investigator 
must be agreed to by Novartis before submission to the IRB/IEC/REB, and a copy of the 
approved version must be provided to the Novartis monitor after IRB/ IEC/REB approval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the patient will not reliabl y compl y, they 
should not be entered in the study .
Additional consent form 
Not applicable.

Novartis Confidential Page 46
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
11.4 Discontinuation of the study
Novartis reserves the right to discontinue this study  under the conditions specified in the 
clinical study  agreement. Specific conditions for terminating the study  are outlined in Section 
4.4.
11.5 Publication of study  protocol and results
Novartis assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinicaltrials.gov. In addition, upon study  completion and 
finalization of the study  report the results of this study  will be either submitted for publication 
and/or posted in a publicly  accessible database of clinical study  results.
11.6 Stud y documentation, record keeping and retention of 
documents
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with Section 
4.9 of the ICH E6 GCP, and regulatory and institutional 
requirements for the protection of confidentiality of subjects. As part of participating in a 
Novartis -sponsored study , each site will permit authorized representatives of the sponsor(s) 
and regulatory  agencies to examine (and when required by applicable law, to copy) clinical 
records for the purposes of qualit y assurance reviews, audits and evaluation of the study 
safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. 
Examples of these original documents and data records include, but are not limited to, hospital 
records, clinical and office charts, laboratory notes, memoranda, subjectsâ€™ diaries or 
evaluation checklists, pharmacy  dispensing records, recorded data from automated 
instruments, copies or transcriptions certified after verification as being accurate and complete, 
microfiches, photographic negatives, microfilm or magnetic media, x-rays, and subject files 
and records kept at the pharmacy , at the laboratories, and medico- technical departments 
involved in the clinical trial.
Data collection is the responsibility  of the clinical trial staff at the site under the supervision of 
the site Principal I nvestigator. The study  case report form (CRF) is the primary  data collection 
instrument for the study . The investigator should ensure the accuracy , completeness, legibility, 
and timeliness of the data reported in the CRFs and all other required reports. Data reported 
on the CRF, that are derived from source documents, should be consistent with the source 
documents or the discrepancies should be explained. All data requested on the CRF must be 
recorded. Any missing data must be explained. Any change or correction to a paper CRF 
should be dated, initialed, and explained (if necessary ) and should not obscure the original 
entry . For electronic CRFs an audit trail will be maintained by the system. The investigator 
should retain records of the changes and corrections to paper CRFs.
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by 
applicable regulations and/or guidelines. The investigator/institution should take measures to 
prevent accidental or premature destruction of these documents.

Novartis Confidential Page 47
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.
11.7 Confidentiality  of study  documents and patient records
The investigator must ensure anon ymity of the patients; patients must not be identified by 
names in any documents submitted to Novartis. Signed informed consent forms and patient 
enrollment log must be kept strictly  confidential to enable patient identification at the site.
11.8 Audits and inspections
Sour ce data/documents must be available to inspections by Novartis or designee or Health 
Authorities.
11.9 Financial disclosures
Financial disclosures should be provided by study personnel who are directly  involved in the 
treatment or evaluation of patients at the site - prior to study  start.
12 Protocol adherence
Investigators ascertain they will apply  due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact Novartis or its agents, if any, monitoring the 
study  to request appro val of a protocol deviation, as no authorized deviations are permitted. If 
the investigator feels a protocol deviation would improve the conduct of the study  this must 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
Novar tis and approved by the IRB/IEC/REB it cannot be implemented. All significant 
protocol deviations will be recorded and reported in the CSR.
12.1 Amendments to the protocol
Any change or addition to the protocol can onl y be made in a written protocol amendment t hat 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC/REB. 
Only  amendments that are required for patient safety  may be implemented prior to 
IRB/IEC/REB approval. Notwithstanding the need for approval of formal protocol 
amendm ents, the investigator is expected to take any immediate action required for the safet y 
of any patient included in this study , even if this action represents a deviation from the 
protocol. In such cases, Novartis should be notified of this action and the I RB/IEC at the stud y 
site should be informed according to local regulations (e.g. UK requires the notification of 
urgent safet y measures within 3 days) but not later than 10 working day s.

Novartis Confidential Page 48
Amended Protocol Version 01 Clean Protocol No. CRAD001C2X01B
13 References (available upon request)
Boulay  A, Lane HA (2007) The mammalian target of rapam ycin kinase and tumor growth 
inhibition. Recent Results Cancer Res. 2007;172:99-124.
Krishna G, Moton A, Lei Ma L
, et al (2009) Effects of oral posaconazole on the 
pharmacokinetic properties of oral and intravenous midazolam: A pha se I, randomized, 
openlabel, crossover study  in healthy  volunteers. Clinical Therapeutics; 31(2): 286 -98.
